Mirati Therapeutics Reaches Analyst Target Price
September 18, 2017 at 09:18 AM EDT
In recent trading, shares of Mirati Therapeutics Inc (MRTX) have crossed above the average analyst 12-month target price of $10.00, changing hands for $11.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..